08:02 EST Protara Therapeutics (TARA) down 18% at $5.66 after equity offering
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics 13.04M share Spot Secondary priced at $5.75
- Protara Therapeutics $75M Spot Secondary; price range $5.75-$6.25
- Protara Therapeutics announces $75M common stock offering
- Protara’s TARA-002: Promising Efficacy and Clear Regulatory Path Justify Buy Rating
- Buy Rating for Protara Therapeutics Driven by Promising Bladder Cancer Drug Trial